Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
3期
进行中（已停止招募）
NCT03375320
| 适应症 | Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1 |
|---|
| 分期 | 3期 |
|---|
| 申办方 | National Cancer Institute (NCI) |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 298 人 |
|---|
| 干预（药物） | Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration |
|---|
| 开始日期 | 2018年10月26日 |
|---|
| 完成日期 | 2023年8月23日 |
|---|
| 结果公布日 | 2024年10月16日 |
|---|
摘要
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Progression-free Survival (PFS)
36 months · months
| Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET]) | 8.4 months |
|---|
| Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET]) | 3.9 months |
|---|
| Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET]) | 13.8 months |
|---|
| Arm IIb (Placebo, Pancreatic NET Cohort [pNET]) | 4.4 months |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。